{"entity":{"id":"nct06153173","kind":"trial","name":"Mirdametinib in Histiocytic Disorders","aka":[],"tldr":"A phase 2 trial of Mirdametinib in Langerhans cell histiocytosis and Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms, run by Children's Hospital Medical Center, Cincinnati, now recruiting.","summary":"Mirdametinib in Histiocytic Disorders is a phase 2 interventional study registered as NCT06153173 by Children's Hospital Medical Center, Cincinnati, with 40 participants planned, started 2024-02-05 and due to reach its primary completion in 2030-03. Interventions recorded: Mirdametinib. Conditions recorded: Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman Disease (RDD), Histiocytic Disorders.\n\nLinked to the drug Mirdametinib because the registry names it among its interventions and Langerhans cell histiocytosis and Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06153173","url":"https://clinicaltrials.gov/study/NCT06153173"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["langerhans-cell-histiocytosis","histiocytoses"],"sections":[],"technologies":[],"targets":[],"drugs":["mirdametinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06153173","phase":"2","setting":"A Phase II Trial of the MEK Inhibitor Mirdametinib in Histiocytic Disorders","sponsor":"Children's Hospital Medical Center, Cincinnati","participation":[{"nct":"NCT06153173","source":"https://clinicaltrials.gov/study/NCT06153173","fetchedAt":"2026-10-07T16:54:16.815Z","studySha256":"d117917853f792a3ec19d41cf99922fceb3a6ce2fef1a0fa5272c876649b8345","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-21","leadSponsor":"Children's Hospital Medical Center, Cincinnati","collaboratorCount":0,"minimumAge":"2 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":40,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["United States"]}],"started":"2024-02-05","startedType":"actual","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06153173/","neighbours":{"cancer":[{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/"},{"id":"langerhans-cell-histiocytosis","kind":"cancer","name":"Langerhans cell histiocytosis (LCH)","route":"/cancers/langerhans-cell-histiocytosis/"}],"drug":[{"id":"mirdametinib","kind":"drug","name":"Mirdametinib","route":"/drugs/mirdametinib/"}]}}